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ABSTRACT
This article performs a systematic liter-
ature review of the last decade studies 
assessing the economic impact of gout. 
The literature review conﬁrms the fact 
that gout reduces productivity and in-
creases annual total healthcare costs, 
since care of gout absorbs relevant 
amounts of healthcare resources. One 
important aspect to be considered is 
represented by prevention and monitor-
ing of the disease after the diagnosis, 
as gout is sometimes underestimated 
by patients and this leads to a reduced 
adherence to follow up and to treat-
ment with consequences on the disease 
course and outcome.
In fact, the lack of prevention and the 
scarce adherence to monitoring in-
crease the number and costs of hospi-
talisation. Prevention, monitoring the 
level of sUA and using a urate-lower-
ing therapy appear to have a central 
role for controlling gout and reducing 
hospitalisation, with positive advan-
tages in terms of healthcare costs and 
healthcare utilisation.
One limitation on the analysis of gout 
related costs, however, resides in the 
fact that the majority of the retrieved 
studies are retrospective and the deﬁni-
tion of the economic impact of the dis-
ease is made difﬁcult by differences in 
inclusion criteria, costs assessment, use 
of gout-related healthcare resources.
Introduction
Although its importance and conse-
quences are underestimated if compared 
to other pathologies, gout is a disease 
that substantially impacts on patients 
and healthcare institutions in terms of 
health costs and utilisation of health-
care services. In fact, reduction of pro-
ductivity and of quality of life, increas-
ing in hospitalisation and in healthcare 
annual costs supported both by patients 
and public healthcare institutions, are 
associated with gout (1). 
In addition, it is well known that in spite 
of these facts, patients tend to underes-
timate the importance of gout and a low 
adherence to monitoring and treatment 
is reported in the literature (2).
Over the last 10 years, health economic 
literature has highlighted the importance 
and impact of gout in terms both of 
healthcare utilisation and of the risk of an 
increase in complexity and costs poten-
tially associated with the underestima-
tion of the relevance of this condition.
The objective of this systematic litera-
ture review is to establish the economic 
impact of gout. The review is based 
on papers published over the last dec-
ade and is designed in accordance with 
the recommendations of the Centre for 
Reviews and Dissemination (3) and of 
the Cochrane Collaboration (4), thereby 
using an established rigorous and repro-
ducible methodology. A protocol was 
developed to deﬁne review questions.
Methods
Published studies in English were 
searched using the main electronic da-
tabase, PubMed MEDLINE. The search 
was performed for the period January 
2002-September 3, 2012. The search 
strategy is as follows: ((“economics
”[Subheading] OR “economics”[All 
Fields] OR “cost”[All Fields] OR “costs 
and cost analysis”[MeSH Terms] OR 
(“costs”[All Fields] AND “cost”[All 
Fields] AND “analysis”[All Fields]) 
OR “costs and cost analysis”[All 
Fields]) AND (“gout”[MeSH Terms] 
OR “gout”[All Fields])) AND 
((“2002/01/01”[PDAT]:”2012/09/
03”[PDAT]) AND “humans”[MeSH 
Terms] AND English[lang] AND 
“adult”[MeSH Terms]).
The publications were assessed for in-
clusion by a 3-step process: i. titles and 
abstracts of all identiﬁed studies were 
assessed by one reviewer and checked 
by a second reviewer; ii. full texts of 
relevant articles were then obtained and 
inclusion criteria applied independently 
by two reviewers. Possible discords be-
tween reviewers were resolved by con-
sensus; iii. data were extracted by one 
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reviewer and then checked by a second 
reviewer.
Inclusion criteria
In the study protocol the reviewers se-
lected publications from the mentioned 
database as follows:
Period: Jan. 2002–Sep. 3, 2012
Language: English
Studies: all articles related to economic 
analysis
Patients: adult ≥18 
Outcomes: direct costs, indirect costs, 
quality of life costs, and cost associated 
with ﬂares.
Exclusion criteria
Studies not published in English and 
all publications before 2002 were ex-
cluded. Conferences proceedings, case 
reports, reviews, systematic reviews, 
letters and commentaries were also ex-
cluded.
Results
As of September 3 2012, 30 articles 
were extracted by the search procedure. 
These were reduced to 14 articles after 
title scrutiny. After abstract review, 12 
publications were included in the analy-
sis, one additional paper was retrieved 
from the bibliography. These 13 pub-
lications were examined and assessed 
for eligibility. On reading the full text 
copies, 10 publications were considered 
relevant to the review (Fig. 1). Two re-
viewers read and examined the full text 
of these publications. 
Full details of the articles in tabular 
form used in the review can be obtained 
on request to corresponding author.
None of the articles provided a full 
economic evaluation (Cost Minimisa-
tion Analysis, Cost Effectiveness Anal-
ysis, Cost Utility Analysis and Cost 
Beneﬁt Analysis). The review is based 
on 9 studies from the USA (5-13) and 
1 from Canada (14); all are retrospec-
tive studies. Of the 3 excluded articles, 
2 articles did not perform an analysis of 
economic impact of gout but reported 
its clinical impact (15, 17); 1 article 
(16) was excluded since it included 
data, methodology and ﬁndings that 
overlapped with the results of  another 
publication (12).
Cost and healthcare utilisation of 
medical services and prescription 
drugs 
Costs analysis for employed population 
has been evaluated by Brook et al. (5) 
and Kleinman et al. (6). Data are poorly 
comparable, in fact while Brook et al. 
assessed total annual costs, Kleinman 
et al. examined loss of productivity.
Interestingly, while the total annual 
costs for employees with gout is high-
er with respect to those without gout, 
data on the loss of productivity associ-
ated with gout does not show difference 
between employees with and without 
gout. Different explanations for this lat-
ter ﬁndings could be sought such as the 
scarcity of data on productivity referred 
to employees affected by gout to serve 
as a measure of comparison, the pres-
ence of a trade-off between the number 
of employees with gout and the avail-
ability of an objective measure of pro-
ductivity, sample dimension (only 7.3% 
of employees with gout falls in the sam-
ple) and a sort of self-selection of peo-
ple with gout that does not accept hard 
jobs. Further studies are therefore need-
ed to better deﬁne this discrepancy.
Brook et al. (5) have showed that cost 
drivers are, among others, medical and 
prescriptions costs, costs associated to 
sick-leave and short-term diseases. The 
total annual costs of employees with 
gout is two time the annual costs for 
employees without gout, on average. 
Location of services, laboratory, hos-
pitals, matter in the differences among 
annual costs.
With a different view and approach, 
Wu et al. (7) calculate healthcare costs 
from a third-party payer perspective. 
In addition, these authors evaluate the 
value of uric acid levels as a control in-
dicator of gout and its relative costs.
Their data show a trend toward an in-
crease in health care costs among pa-
tients with either high serum urate lev-
els, gout or tophi. In a period of one year 
after a diagnosis of gout, for patients 
aged over 65, direct costs associated 
to any kind of conditions (either gout 
or increased serum urate levels) was 
$876 (5.9%) of the total health costs 
($14,734 of 2005 dollars) registered in 
the period, mainly related with inpatient 
(57.6%) and outpatient (23.6%) costs, 
while only a small part was related with 
drugs (7.1%), emergency care (2.4%) 
and other services (9.4%). In addition, 
patients with tophi had higher costs than 
patients without. Finally, high levels 
(>9 mg/dL) of serum UA are associated 
to an increasing of $3,103 in costs for 
all-cause health and $276 health costs 
associated to gout, with respect to a low 
level of sUA. 
In line with the previous authors, Hanly 
et al. (14) examined patients with gout 
over  65 years of age in Nova Scotia 
(Canada). The study included costs 
associated to physician claims, hospi-
tal admissions, ambulatory visits, and 
Pharmacare prescriptions. In the gout 
cohort an average overall healthcare 
Fig. 1. PRISMA ﬂow
diagram for cost studies 
in gout.
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cost differential of C$134 per month 
was observed, which was of C$8,020 
over 5 years of follow up. Hospital uti-
lisation was the most important item in 
determining costs, probably due to co-
morbidities associated to gout. 
This hypothesis seems sustained by 
Nitchaikulvatana et al. (12) showing 
that complications for gout in hospital 
also increase the length of stay with a 
daily cost of $1,762. In addition, these 
authors observed that 29% of admis-
sions for gout on the total examined 
were preventable cases. Assuming that 
this percentage is also true for the an-
nual population that have a ﬁrst diag-
nosis of gout, the annual costs for the 
lack of an efﬁcient prevention and the 
relative use of hospitalisation would be 
about $32 million.
Increasing health care costs are also 
related with disease severity; the stud-
ies by Wu et al. (10) and Park et al. 
(13) reported increased medical and 
pharmacy costs as the level of sUA in-
creases. Wu et al. (10) analyse the cor-
relation between gout ﬂares and sUA 
levels, and the relative cost of gout 
ﬂares in old people (over 65 aged). It 
is observed that people with high level 
of sUA have a higher probability of a 
ﬂare in 1 year. In aggregate, the annual 
number of ﬂares increases of 11.9% per 
unit of increasing in sUA level above 6 
mg/dl. For patients with high level of 
sUA, the total health cost associated to 
gout is $2,555 per episode with a dif-
ference of $356 with respect to patients 
with a normal level of sUA. 
High levels of sUA gout cases in eld-
erly and healthcare cost increasing are 
positively and mutually correlated.  
Similarly Halpern et al. (11)  showed a 
positive association between costs for 
gout ﬂare and sUA levels. For a level 
of sUA less than 6.0 mg/dl the average 
cost is $259 ($147 median); $477 on 
average with a sUA value  from 6 to 9 
mg/dl ($171 median); $562 on average 
with a sUA value greater than 9 mg/dl 
($189 median). 
Another important variable from an 
economic perspective is represented by 
the way patients consider their disease 
and patients’ willingness to pay for gout 
care, as this also gives an indication on 
patients’ perception of the severity of 
this condition and on possible impact 
on future quality of life, and on future 
outcome and development of gout re-
lated comorbidities. In a study assess-
ing patients with chronic gout, Khanna 
et al. (8) observed that the willing to 
monthly pay for gout is about $52 on av-
erage ($25 median) and that this value 
was related with income and number of 
gouty attacks. While gender and ethnic 
differences did not matter in the level 
of willing to pay for gout, a difference 
was observed with respect to age and 
health condition, as younger patients 
and people that ranked gout in the ﬁrst 
position of their concern were willing to 
pay more.
On a similar type of study, Khrishnan 
et al. (9) examined the magnitude of 
healthcare utilisation (use of ambu-
latories for gout treatment and visits) 
for gout in USA and its high economic 
impact. They observed that there is a 
small but consolidated use of healthcare 
services for gout in USA (3.9 million of 
ambulatory visits on a total of 973 mil-
lion regard gout), with age and sex dif-
ferences. Interestingly, Asiatic patients 
had a probability to have a gout visit 2.7 
times higher than Caucasian patients, 
but a lower percentage of them was re-
ceiving allopurinol.
Discussion and conclusions 
Literature data suggest that in the US 
every year new cases of acute gout ac-
count for a mean of $27.4 million of 
direct costs (2). 
The most recent literature on the eco-
nomic impact of gout is not consoli-
dated and is mainly represented by 
retrospective studies. Differences in 
patients characteristics, data retrieve-
ment and models to measure costs and 
gout-related healthcare resource con-
sumption make these data difﬁcult to 
be compared and summarised.
In spite of these difﬁculties, the present 
systematic literature review allows 
some observations. Agreement exists 
on the fact that the care of gout con-
sumes a large size of resources mean-
ing high costs. 
The most important determinants of 
costs are represented by in and out pa-
tient’s care, while drugs costs cover 
only a limited part. This fact could be 
attributed to the fact that, up to now, the 
drugs largely used in the treatment of 
this condition are less expensive and/or 
off patent.
Increased disease costs are related also 
with the severity of the disease, as some 
studies have shown that higher sUA 
levels and ﬂares determine an increas-
ing in costs. In addition, patients seem 
to have a low utilisation of health care 
resources. This observation is coherent 
with other data showing a low adher-
ence to therapy and follow up among 
gout patients in spite of emerging Rec-
ommendations developed by scientiﬁc 
societies, similarly to what is reported 
in other rheumatologic diseases (18-
20).
The lack of prevention and regular 
monitoring increases the number and 
costs for hospitalisation. This factor, 
associated with the management of co-
morbidities gout-related, increases the 
difference in annual healthcare costs of 
patients with gout with respect to annu-
al health costs for people without gout.
Future studies should address, in a pro-
spective and detailed way (21), the is-
sue of the loss of productivity and ana-
lyse the correlations between imple-
mentation of recommendations, quality 
of care indicators and economic issues 
in gout as in other rheumatic diseases 
(22-28). 
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